# K130197: BD Phaseal Closed System Transfer Device - P55

- Pathway: 510(k) (Special)
- Applicant: Becton, Dickinson and Company
- Decided: Feb 27, 2013 after 30 days
- Product code: ONB (Closed Antineoplastic And Hazardous Drug Reconstitution And Transfer System)
- Device class: 2
- Regulation: 21 CFR 880.5440
- Recalls of this device: 1 (0 Class I)
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 7 generations back to K883614 (1988). 13 ancestors in all.
19 later devices descend from it; 3 cite it directly.
0 of 33 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K123213: BD Phaseal Closed System Transfer Device, Becton, Dickinson & CO (2013)

## Most influential descendants
- K141448: Tevadaptor Closed Drug Reconstitution and Transfer System (2015), 9 descendants of its own
- K132899: Equashield Closed System Drug Transfer Device (CSTD) (2014), 6 descendants of its own
- K170706: Equashield Closed System drug Transfer Device (CSTD) (2017), 5 descendants of its own
- K201460: Closed System Transfer Device (2022), 3 descendants of its own
- K192866: Chemfort CSTD (2020), 3 descendants of its own

## Recalls of this device
- Jun 16, 2025 · Class II · Z-2453-2025: Closed system drug transfer devices were shipped to the U.S. market without a U.S. version of the instructions for use, which could be an issue if a healthcare professional is prompted to review it.

## Indications for use
The PhaSeal system is an airtight and leakproof closed system drug transfer device (CSTD) that mechanically prohibits the transfer of environmental contaminants into the system and the escape of drug or vapor contractions outside the system thereby minimizing individual and environmental exposure to drug vapor, aerosols and spills. The PhaSeal system also prevents microbial ingress.

Source page: https://510kreport.com/device/K130197
Methodology: https://510kreport.com/methodology